Earnings Report: GlaxoSmithKline (PSX: GLAXO) today reported Financial Results for the Three and Six months ended June 30, 2017

Unconsolidated Profit and Loss Account - For the Six Months Ended

Key Financials

Jan - June, 2017

Jan - Jun, 2016

% Change

Amounts in PKR ‘000

Sales

16,208,185

12,916,465

25%

Cost of Sales

11,824,067

9,510,709

24%

Gross Profit

4,384,118

3,405,756

29%

Selling, Marketing and Dist: Expenses

1,478,058

1,355,368

9%

Admin: Expenses

482,952

490,813

-2%

Other Operating Expenses

222,013

137,921

61%

Other Income

294,599

196,516

50%

Profit from Operations

2,495,694

1,618,170

54%

Finance Cost

9,761

8,598

14%

Profit before Taxation

2,485,933

1,609,752

54%

Taxation

1,027,937

675,049

52%

Profit after Taxation from Continued Operations

1,457,996

934,523

56%

(Loss)/Profit after Taxation from dis-continued Operations

(31,721)

138,816

-123%

Total Profit after Operations

1,426,275

1,073,339

33%

EPS - Continued Operations

4.58

2.93

56%

EPS - Discontinued Operations

(0.10)

0.44

-123%

EPS

4.48

3.37

33%